Life sciences-focused venture capital firm Medicxi Ventures has agreed to invest up to €9m in Mavalon. Mavalon is developing an orally available small molecule able to induce Glial
ONIVYDE is the first and only approved treatment option for this patient population. With this approval, Shire is authorized to market ONIVYDE in the 28 Member States of
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government. AML is the most lethal of the
The establishment of Clinigen KK further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen KK will transfer the
The approval allows for the use of Tecentriq, a PD-L1 inhibitor, by patients whose disease progressed during or after platinum-containing chemotherapy, and whose disease progressed on an FDA–approved
Follitropin delta is the first recombinant follicle stimulating hormone (FSH) derived from a human cell line. It has been developed for individualized dosing depending on a woman’s serum
The entity results from the merger of Antegrin and Cascadia and the consolidation of their respective management teams. Financial terms of the deal were not disclosed. The new
The company intends to escalate its appeal to the next supervisory level of the FDA. This is an iterative process and the company anticipates that multiple cycles of
The initial fund target was $550M. Sofinnova was founded in 1974 and is headquartered in Menlo Park, California with offices in Menlo Park, Ca. and San Diego, Ca.
INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the U.S. It is approved for the treatment of: adult
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.